Biologics increase the risk of SARS ‐ CoV ‐2 infection and hospitalization, but not ICU admission and death: Real‐life data from a large cohort during red‐zone declaration

A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis

(2020) Lynda Spelman et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal

(2020) Hasan K. Siddiqi et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Why tocilizumab could be an effective treatment for severe COVID-19?

(2020) Binqing Fu et al.   Journal of Translational Medicine

Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China

(2020) Guqin Zhang et al.   JOURNAL OF CLINICAL VIROLOGY

Psoriasis and Respiratory Comorbidities: The Added Value of Fraction of Exhaled Nitric Oxide as a New Method to Detect, Evaluate, and Monitor Psoriatic Systemic Involvement and Therapeutic Efficacy

(2018) Pierachille Santus et al.   Biomed Research International

Safety of Systemic Agents for the Treatment of Pediatric Psoriasis

(2017) Inge M. G. J. Bronckers et al.   JAMA Dermatology

Increased airway inflammation in patients with psoriasis

(2016) G. Damiani et al.   BRITISH JOURNAL OF DERMATOLOGY